US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

Author:

Ravandi Farhad1,Othus Megan2,O'Brien Susan M.3,Forman Stephen J.4,Ha Chul S.5,Wong Jeffrey Y. C.4,Tallman Martin S.6,Paietta Elisabeth78,Racevskis Janis78,Uy Geoffrey L.9,Horowitz Mary10,Takebe Naoko11,Little Richard11,Borate Uma12,Kebriaei Partow13,Kingsbury Laura2,Kantarjian Hagop M.1,Radich Jerald P.14,Erba Harry P.15,Appelbaum Frederick R.16

Affiliation:

1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;

2. SWOG Statistical Center, Seattle, WA;

3. University of California—Irvine, Orange, CA;

4. City of Hope National Medical Center, Duarte, CA;

5. University of Texas Health Science Center, San Antonio, TX;

6. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;

7. Cancer Center, Montefiore Medical Center, Bronx, NY;

8. Albert Einstein College of Medicine, New York, NY;

9. Division of Oncology, Washington University School of Medicine, St. Louis, MO;

10. Medical College of Wisconsin, Milwaukee, WI;

11. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD;

12. University of Alabama at Birmingham, Birmingham, AL;

13. Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX;

14. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

15. University of Alabama at Birmingham (UAB) and UAB Comprehensive Cancer Center, Birmingham, AL; and

16. Fred Hutchinson Cancer Research Center, Seattle, WA

Abstract

Key Points Addition of dasatinib to chemotherapy followed by allogeneic stem cell transplant is well tolerated in younger patients with Ph+ ALL. Landmark analysis showed statistically superior advantages for relapse-free and overall survival for the transplanted patients.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3